Metsera, Inc. (NASDAQ:MTSR) saw a surge in its stock price on Thursday, hitting a new all-time high of $82.79 before closing at $81.55, up 14.25%. This increase was fueled by a bidding war between Pfizer and Novo Nordisk, both vying to acquire the company for $10 billion. The battle began in January, with both pharmaceutical giants seeking to dominate the weight-loss market. Pfizer had initially agreed to buy Metsera, but later rescinded after Novo Nordisk made a higher offer, leading to a lawsuit from Pfizer claiming anti-competitive behavior. Investors are advised to consider other AI stocks for potential high returns.

Read more at Yahoo Finance: Metsera (MTSR) Hits New High on Billion-Dollar Bidding War